Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794560 | PMC |
| http://dx.doi.org/10.1200/JOP.2005.1.4.155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of machine learning algorithms and computational structural validation of CYP2D6 in predicting the therapeutic response to tamoxifen in breast cancer.
Eur Rev Med Pharmacol Sci
December 2024
Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Objective: CYP2D6 plays a critical role in metabolizing tamoxifen into its active metabolite, endoxifen, which is crucial for its therapeutic effect in estrogen receptor-positive breast cancer. Single nucleotide polymorphisms (SNPs) in the CYP2D6 gene can affect enzyme activity and thus impact tamoxifen efficacy. This study aimed to use machine learning algorithms (MLAs) to identify significant predictors of Breast Cancer-Free Interval (BCFI) and to apply bioinformatics tools to investigate the structural and functional implications of CYP2D6 SNPs.
View Article and Find Full Text PDFPharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications.
Pharmacogenomics
November 2024
Department of Anatomy, Genetics & Biomedical Informatics, Faculty of Medicine, University of Colombo, Sri Lanka.
Article Synopsis
- Pharmacogenomics is gaining traction in South Asia, particularly in Sri Lanka, aiming to enhance drug therapies and minimize side effects for patients.
- A comprehensive review analyzed research in Sri Lanka, where studies were classified into categories like clinical correlational, descriptive, and novel assay development; 11 articles and 8 theses were reviewed.
- While progress has been made, additional clinical studies and a wider scope of genomic research are necessary, alongside efforts to address challenges like funding and public awareness, to successfully implement personalized medicine in the region.
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Breast Cancer Res Treat
October 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Article Synopsis
- - The study examined how genetic variations in the CYP2D6 gene and resulting endoxifen levels affect breast cancer outcomes in patients taking tamoxifen.
- - Conducted with 113 patients with advanced hormone receptor-positive breast cancer, it compared those with poor CYP2D6 metabolism to those with normal or intermediate metabolism regarding progression-free survival (PFS).
- - Results showed no significant relationship between CYP2D6 status, endoxifen concentrations, and PFS, possibly due to the small sample size and issues with sample collection in the trial.
Reply to "Inadequate representation of individuals of African ancestry in pharmacogenetics of tamoxifen research".
Clin Transl Sci
October 2024
Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Inadequate representation of individuals of African ancestry in pharmacogenetics of tamoxifen research.
Clin Transl Sci
September 2024
Botswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!